Walvax沃森生物

CN
EN

Help Everyone Live a Healthy Life

Walvax Publishes Immunogenicity and Safety Data

from Phase 3 Clinical Study of PCV13

in Frontiers in Microbiology

Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (HPV-2) has been approved by NMPA

ㅤㅤㅤ

ㅤㅤㅤ

ㅤㅤㅤ

ㅤㅤㅤ

CEPI, Shanghai Zerun Biotech and Walvax Biotech expand collaboration to develop COVID-19 multi-variant vaccine

Safety and Immunogenicity Data

from Phase 1 Clinical Study of SARS-CoV-2 mRNA Vaccine

Advanced, Modular and Digital mRNA Workshop

Investors

Walvax aims to become a high-quality, cost-effective and sustainable global vaccine producer. 

R&D

We have abundant blockbuster pipelines in clinical stage, and keep investing a significant amount of revenue into R&D.  

Products

We have successfully developed and licensed 8 vaccines and protected hundreds of millions of people from diseases. 

About Walvax

Founded in 2001, Walvax is mainly engaged in research and development, manufacturing and distribution of safe and efficacious vaccines. With the purpose of “Help everyone live a healthy life”, Walvax aims to be a leader in public health, sustainably providing high-quality and innovative products to protect against the world’s deadliest diseases.

Learn More
541.1
USD541.1 million revenue in 2021
17.8%
17.8% increase in revenue since 2020
8
8 new vaccines and 1 siRNA therapeutics under development
65
65 authorized invention patents at home and abroad
10+
10+ patents application in progress
94.6%
94.6% cities covered in China
18
Products exported to 18 countries
21
21 countries registration in progress
80
Engaged 80+ partners in 5 continents

Join Us

You’ll partner with colleagues of diverse backgrounds and abilities. 

Responsibility

We are focused on the areas of greatest need.